Research Identifies Potential Biomarkers for Diagnosing Hypermobile Ehlers-Danlos Syndrome and Hypermobility Disorders (HSD)

A new study funded by The Ehlers-Danlos Society has identified potential biomarkers that could revolutionize the diagnosis of hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD). The study, published in the American Journal of Medical Genetics, highlights the discovery of a specific fibronectin fragment and a collagen I fragment in the blood of individuals with hEDS and HSD. These fragments were absent in healthy controls and people with other conditions, suggesting that they could serve as reliable biomarkers for diagnosing these challenging-to-diagnose conditions. If validated, these findings could lead to the development of the first blood test for hEDS and HSD, potentially reducing the average diagnostic timeline of 12 years.

Summary of Key Findings

The study examined blood samples from 466 adults, including individuals diagnosed with hEDS, HSD, and other control groups. Researchers detected a 52 kDa fibronectin fragment consistently in all hEDS and HSD patients, a fragment absent in healthy controls and other disease groups like arthritis. Additionally, a collagen I fragment was also found in individuals with hEDS and HSD. These discoveries suggest a common biological pathway in both hEDS and HSD, offering the possibility of a future diagnostic blood test. Further research and validation are required to confirm these biomarkers' utility in clinical practice.

What Did the Study Find?

Researchers analyzed blood samples from 466 adults, including 94 people with diagnosed hEDS and 80 with HSD. Their findings could be a game changer:

1. Fibronectin Fragment: A 52 kDa fragment of fibronectin was detected in all individuals with hEDS and HSD. Notably, this fragment was absent in healthy controls, individuals with other types of Ehlers-Danlos syndrome, and those with various forms of arthritis. This consistency suggests that this fibronectin fragment could be a reliable biomarker for both hEDS and HSD.
2. Collagen I Fragment: The study also identified a fragment of collagen I in individuals with hEDS and HSD. While this fragment was present in other conditions as well, its consistent appearance in hEDS and HSD subjects may offer additional insights into the underlying mechanisms of these disorders.

What Could This Mean?

The discovery of these biomarkers offers several critical insights:

• Faster Diagnosis: A blood test based on these biomarkers could dramatically shorten the average diagnostic timeline, which is currently around 12 years.
• Improved Patient Care: Early and accurate diagnosis could lead to more personalized treatment plans, improving patient outcomes.
• Questioning Diagnostic Categories: The shared biological markers between hEDS and HSD suggest that these conditions may not be as distinct as previously thought, potentially leading to a reclassification of these disorders as part of a continuum.

What Are the Next Steps?

While the findings are promising, further research is needed. The Ehlers-Danlos Society is sponsoring additional studies to validate these biomarkers in larger, more diverse groups. If these studies confirm the results, a diagnostic blood test could become available for clinical use, fundamentally changing how hEDS and HSD are diagnosed and treated.

Conclusion

This new research represents a major step forward in the quest for a reliable, objective diagnostic test for hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders. If validated, the discovery of fibronectin and collagen fragments as biomarkers could drastically improve the diagnostic process and our understanding of these complex conditions. As the scientific community works to confirm and expand on these findings, patients and healthcare providers alike have reason to be hopeful for the future of hEDS and HSD diagnosis and treatment.

Deep Dive into the Research

For those seeking a more detailed understanding of this groundbreaking study, let’s dive deeper into the scientific findings and methodologies of the research.

Study Design and Methodology

This study involved the analysis of blood samples from 466 adults: 94 diagnosed with hEDS, 80 with HSD, and various control groups including healthy individuals, and patients with other Ehlers-Danlos syndromes and types of arthritis. The research team employed Western blot analysis to detect protein fragments in the plasma, focusing specifically on fragments of connective tissue proteins such as fibronectin and collagen.

Key Techniques

• Western Blotting: This technique allowed researchers to identify the protein fragments present in blood plasma samples, providing a clear comparison between the hEDS/HSD group and control groups.
• Protein Fragment Analysis: Researchers paid particular attention to identifying fragments of extracellular matrix proteins, which are critical for maintaining the structural integrity of tissues.

Key Findings and Their Implications

1. Fibronectin Fragment (52 kDa):
   • The presence of the 52 kDa fibronectin fragment in all individuals with hEDS and HSD is particularly significant. Fibronectin is a glycoprotein involved in cell adhesion and tissue repair, and the consistent appearance of this fragment points to a potential common pathological mechanism in both conditions. This discovery may explain the tissue fragility and joint hypermobility seen in both hEDS and HSD.
   • Implication: The fibronectin fragment could serve as a key marker in diagnosing hEDS and HSD, distinguishing these conditions from other connective tissue disorders. Its absence in other EDS types and conditions like rheumatoid and psoriatic arthritis suggests high specificity.
2. Collagen I Fragment:
   • A fragment of collagen I was also found in the plasma of all individuals with hEDS and HSD. Collagen I is a major structural protein in connective tissues, including skin, tendons, and ligaments. While this fragment was not unique to hEDS and HSD (being found in other conditions as well), its presence in these disorders supports the theory of connective tissue abnormalities playing a central role in their pathology.
   • Implication: While not as specific as the fibronectin fragment, the collagen I fragment could contribute to a broader understanding of the connective tissue defects in hEDS and HSD.
3. Distinguishing hEDS and HSD:
   • One of the most intriguing findings of the study is the overlap in biological markers between hEDS and HSD, suggesting a shared pathophysiology. Traditionally, hEDS and HSD have been treated as distinct conditions, but the presence of the same fibronectin fragment in both groups raises the possibility that they are part of a spectrum rather than separate entities.
   • Implication: This finding could prompt a reevaluation of how hEDS and HSD are classified, with future diagnostic criteria potentially considering them as variations of the same disorder.

Broader Implications for hEDS and HSD Research

This study is not only a step forward for diagnosis but also opens the door to new research avenues. Understanding the biological basis of hEDS and HSD could lead to:

• Targeted Therapies: As we uncover more about the molecular mechanisms underlying these conditions, there may be potential for developing therapies aimed at correcting or mitigating these connective tissue abnormalities.
• Refined Classification Systems: The similarities between hEDS and HSD in terms of biomarkers may lead to changes in how these disorders are diagnosed and managed clinically.
• Shorter Diagnostic Pathways: If a blood test based on these biomarkers is validated, it could significantly reduce the need for complex and subjective diagnostic evaluations, leading to faster and more accurate diagnoses.

Next Steps in Research and Clinical Application

While the findings of this study are exciting, they are not yet ready for clinical use. The research team has called for:

• Validation Studies: Additional studies involving larger and more diverse patient groups are needed to confirm these findings.
• Clinical Trials: If the biomarkers are validated, clinical trials could explore how well these markers perform in real-world diagnostic settings and assess their reliability across various populations.
• Potential Development of a Blood Test: If successful, this could be the first blood test available for diagnosing hEDS and HSD, representing a major advancement in the field.

‍

Frequently Asked Questions (FAQs)

How do you diagnose Ehlers-Danlos syndrome?

The diagnosis of Ehlers-Danlos syndrome (EDS) is usually based on a combination of clinical evaluation, medical history, and physical tests. For hypermobile EDS (hEDS), diagnosis primarily relies on assessing joint hypermobility using the Beighton score, alongside evaluating skin characteristics and family history. For other types, genetic testing can identify specific mutations in collagen or connective tissue-related genes. A healthcare provider, often a geneticist or rheumatologist, will typically conduct a thorough evaluation to rule out other conditions before confirming a diagnosis.

Does EDS show up in blood work?

Currently, no standard blood test can diagnose Ehlers-Danlos syndrome, particularly hEDS. Most types of EDS, including hEDS, are diagnosed through clinical criteria rather than blood tests. However, a recent study identified potential blood-based biomarkers, like a fibronectin fragment, which could lead to the development of a diagnostic blood test for hEDS and hypermobility spectrum disorders (HSD) in the future. Other types of EDS that involve known genetic mutations can be detected through genetic testing, but not through typical blood work.

How does this new biomarker compare to existing diagnostic methods for hEDS and HSD?

The newly discovered biomarker, specifically the 52 kDa fibronectin fragment, has the potential to offer a more objective and accurate diagnosis compared to the current methods, which rely on subjective clinical observations like joint hypermobility. If validated, this biomarker could provide a measurable biological marker, making the diagnostic process more reliable.

What are the implications of this biomarker for patients who are already diagnosed with hEDS or HSD?

For those who already have a diagnosis of hEDS or HSD, this biomarker could serve as a way to confirm the diagnosis more objectively. It may also offer additional insights into the biology behind their condition, potentially guiding more personalized treatment strategies in the future.

How soon could a blood test based on this biomarker be available in clinical practice?

While the initial findings are promising, the development of a blood test will require further research, including larger validation studies. If successful, it could take several years before a blood test is available for widespread clinical use, as the process involves multiple phases of clinical trials and regulatory approvals.

Are there any limitations to using these biomarkers in diagnosing hEDS and HSD?

As with any diagnostic tool, potential limitations exist. For instance, individual variability between patients or the presence of these markers in other conditions could impact the test's specificity. Ongoing studies aim to clarify these limitations and ensure the test is accurate and reliable across different populations.

How specific is the biomarker to hEDS and HSD? Could it be present in other conditions?

The 52 kDa fibronectin fragment appears to be highly specific to hEDS and HSD, as it was not found in healthy controls or individuals with other forms of EDS or arthritis. However, the collagen I fragment identified in the study was also present in other conditions, so more research is needed to establish the full specificity of these biomarkers.

What further research is needed to confirm the validity of this biomarker?

Further studies are necessary to replicate the initial findings in larger, more diverse patient groups. These studies will assess the consistency of the biomarker in hEDS and HSD patients, ensuring it can reliably be used in diagnosis. The Ehlers-Danlos Society is funding ongoing research to validate these biomarkers.

How could this biomarker influence the future of hEDS and HSD treatment?

If validated, this biomarker could open the door to more personalized treatment options. By understanding the biological mechanisms behind hEDS and HSD, healthcare providers might be able to tailor treatments based on each patient’s specific characteristics, leading to more effective care.

Will this biomarker help in differentiating between hEDS and HSD, or are these conditions considered a spectrum of the same disorder?

The study’s findings suggest that hEDS and HSD may share similar biological markers, which supports the idea that these conditions could be part of a single spectrum rather than entirely distinct disorders. This could influence how these conditions are classified and treated in the future.

What are the markers for Ehlers-Danlos syndrome?

While there are no definitive blood-based markers for most forms of EDS, certain types like classical EDS and vascular EDS are associated with specific genetic mutations, such as in the COL5A1 and COL3A1 genes. For hEDS, the newly discovered fibronectin fragment may serve as a potential biomarker, but it still requires further validation.

How do I get EDS genetic testing?

Genetic testing for EDS is usually ordered by a healthcare provider, often a geneticist. Testing is available for many types of EDS with known genetic mutations, like classical or vascular EDS. Your doctor will typically refer you for genetic testing if there is a suspicion of one of these types based on clinical symptoms. Unfortunately, there is no genetic test for hypermobile EDS at this time.

‍
Source: 

‍
Ritelli, Marco, et al. "Bridging the Diagnostic Gap for Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: Evidence of a Common Extracellular Matrix Fragmentation Pattern in Patient Plasma as a Potential Biomarker." American Journal of Medical Genetics Part A, vol. 192, no. 9, 2024, pp. 987-1001. Wiley Online Library, https://doi.org/10.1002/ajmg.a.63857.
‍
For more detailed information, you can access the complete study here.

‍